falomorning.blogg.se

Like OTO-104, Spi­ral’s top pro­gram, SPT-2101, is a sus­tained-re­lease steroid for­mu­la­tion, ex­cept it uti­lizes a dif­fer­ent drug de­liv­ery plat­form to reach the in­ner ear. The com­pa­ny raised $8.25 mil­lion ear­li­er this year to fund its work on ther­a­pies for in­ner ear dis­or­ders. “The ac­quired da­ta will help us de­fine the tar­get prod­uct pro­file and clin­i­cal study de­sign as we build these in­to new as­sets in our pipeline,” he wrote. Spi­ral said it “plans to lever­age valu­able da­ta and in­sights gained from Oton­o­my’s 15 years of ex­pe­ri­ence in the field of in­ner ear dis­or­ders” to ac­cel­er­ate its own lead drug’s path to late-stage clin­i­cal tri­als.įor the two as­sets oth­er than OTO-104, “the plan is to re­for­mu­late in­to our nov­el drug de­liv­ery plat­form,” Spi­ral CEO Hugo Peris wrote in an email to End­points News.